RECEIVABLES	6 Months Ended
Jun. 30, 2016
Receivables [Abstract]
RECEIVABLES	RECEIVABLES Accounts Receivables Accounts receivable, net of reserves for prompt pay discounts and doubtful accounts, was $16.6 million and $12.5 million at June 30, 2016 and December 31, 2015, respectively. The total reserves for both periods were immaterial. Notes Receivables Notes receivable arose from the Company's sale of a Pediatric PRV in July 2015 to Sanofi for $245.0 million. $150.0 million was received upon closing, and $47.5 million is due on each of the first and second anniversaries of the closing. In accordance with GAAP, the Company recorded the future short term and long term notes receivable at their present value of $46.2 million and $44.9 million, respectively, at the date of the sale using a discount rate of 2.8%. The accretion on the notes receivable totaled $0.6 million and $1.3 million for the three and six month periods ending June 30, 2016, respectively, and is recorded in interest expense, net, in the Consolidated Statements of Operations and Comprehensive Income (Loss). The present value of the current and long-term notes receivable are $47.5 million and $46.2 million, respectively, and $46.8 million and $45.6 million, respectively, as of June 30, 2016 and December 31, 2015. The Company noted no indications for impairment as of June 30, 2016.

RECEIVABLES

6 Months Ended

Jun. 30, 2016

Accounts Receivables

Accounts receivable, net of reserves for prompt pay discounts and doubtful accounts, was $16.6 million and $12.5 million at June 30, 2016 and December 31, 2015, respectively. The total reserves for both periods were immaterial.

Notes Receivables

Notes receivable arose from the Company's sale of a Pediatric PRV in July 2015 to Sanofi for $245.0 million. $150.0 million was received upon closing, and $47.5 million is due on each of the first and second anniversaries of the closing. In accordance with GAAP, the Company recorded the future short term and long term notes receivable at their present value of $46.2 million and $44.9 million, respectively, at the date of the sale using a discount rate of 2.8%. The accretion on the notes receivable totaled $0.6 million and $1.3 million for the three and six month periods ending June 30, 2016, respectively, and is recorded in interest expense, net, in the Consolidated Statements of Operations and Comprehensive Income (Loss). The present value of the current and long-term notes receivable are $47.5 million and $46.2 million, respectively, and $46.8 million and $45.6 million, respectively, as of June 30, 2016 and December 31, 2015. The Company noted no indications for impairment as of June 30, 2016.